Izvorni znanstveni članak
https://doi.org/10.2478/acph-2023-0045
Exploring adherence in patients with advanced breast cancer: focus on CDK4/6 inhibitors
MATEA BAKOVIĆ
; University of Zagreb Faculty of Pharmacy and Biochemistry, 10 000 Zagreb, Croatia
MARTINA BAGO
; Andrija Štampar Teaching Institute of Public Health, 10 000 Zagreb, Croatia
LUCIJA BENIĆ
; University of Zagreb Faculty of Pharmacy and Biochemistry, 10 000 Zagreb, Croatia
MAGDALENA KRAJINOVIĆ
; University of Zagreb Faculty of Pharmacy and Biochemistry, 10 000 Zagreb, Croatia
TAJANA SILOVSKI
; University Hospital Centre, Department of Oncology, 10 000 Zagreb, Croatia; University of Zagreb School of Medicine, 10 000 Zagreb, Croatia
NATALIJA DEDIĆ PLAVETIĆ
; University Hospital Centre, Department of Oncology, 10 000 Zagreb, Croatia; University of Zagreb School of Medicine, 10 000 Zagreb, Croatia
LU TURKOVIĆ
; University of Zagreb Faculty of Pharmacy and Biochemistry, 10 000 Zagreb, Croatia
MIRANDA SERTIĆ
MAJA ORTNER HADŽIABDIĆ
; University of Zagreb Faculty of Pharmacy and Biochemistry, 10 000 Zagreb, Croatia
Sažetak
Treatment adherence is crucial for optimal outcomes in advanced breast cancer, but can be challenging due to various factors, i.e. patients' attitudes and behavior upon diagnosis, and complex therapies with high adverse effect rates. Our aim was to explore the adherence to oral anticancer medications (OAM) in women with advanced breast cancer, focusing on cyclin-dependent kinase 4 and 6 inhibitors (CDKI), and identify factors associated with the adherence. We conducted a cross-sectional study at the University Hospital Centre Zagreb, Croatia, involving women with stage IV advanced breast cancer receiving OAM. Data collection included a questionnaire assessing socio-demographic and clinical information, Beck Depression Inventory-II for depressive symptoms, Medication Adherence Report Scale (MARS-5) for adherence to OAM, and Beliefs about Medicines Questionnaire. Plasma concentrations of CDKI were confirmed by LC-MS/MS in three randomly selected participants. A total of 89 women were included. The most prescribed OAMs were anti-estrogen (71.3 %) and CDKI (60.9 %). MARS-5 scores (mean: 24.1 ± 1.6) correlated with CDKI plasma concentrations. Forgetfulness was the primary reason for non-adherence (25.9 %). Women receiving CDKI (p = 0.018), without depressive symptomatology (p = 0.043), and with more positive beliefs about medicines were more adherent (p < 0.05). This study enhances understanding of medication adherence in advanced breast cancer and identifies influential factors.
Ključne riječi
advanced breast cancer; oral anticancer therapy; CDK 4/6 inhibitors; adherence; depressive symptoms, beliefs about medicines
Hrčak ID:
310572
URI
Datum izdavanja:
30.12.2023.
Posjeta: 190 *